Top Tweets for #SPIMACO

$NWBO The potential in DCVax technologies that SPIMACO recognized is significant — it could be what determines how many shares the Saudi sovereign funds decide to acquire, and at what price. If SPIMACO saw potential in combining the DC vaccine with the influenza and pneumococcal vaccines to treat cancer, and Saudi Arabia decided to produce those vaccines at its new 42,000 m² vaccine manufacturing facility, that would be truly exciting! https://t.co/z7wouetnEi Linda Powers, the Company’s CEO, commented: “We are excited to join forces with SPIMACO as a leader in Saudi Arabia’s building of a major global biotechnology hub. SPIMACO has been developing state-of-the-art facilities and acquiring state-of-the-art technologies for this hub. We are gratified that SPIMACO sees the important potential of DCVax technologies, and we look forward to contributing to these developments.” Randomized Phase I/II Pilot Study of the Immunogenicity of Cyclophosphamide With Peptide Pulsed Mature Dendritic Cells for Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Carcinoma https://t.co/Hxz9YanNNn •Arm-1: Trivalent killed influenza vaccine + Prevnar + DC-Ova •Arm-2: Trivalent killed influenza vaccine + Prevnar + DC-Ova + Cyclophosphamide Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission https://t.co/QsORpjrx8A https://t.co/qpOyoccN0M With an investment of approximately USD 133 million (SAR 500 million), the project spans 42,000 m² and will employ approximately 150 people upon operationalization. Production will include influenza, COVID-19, pneumococcal, meningitis, and rotavirus vaccines, supporting national immunisation programs and export plans. https://t.co/7tZrV3fEWO https://t.co/HCJyNr7avW With 80% of construction work completed, the Vaccine Industrial Company project is entering its final stages, paving the way for production to begin next year. A significant milestone in localizing vaccine manufacturing and building sustainable national capabilities that strengthen the Kingdom’s pharmaceutical security.